Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
BMC Cancer
2018 Feb 17;181:193. doi: 10.1186/s12885-018-4077-3.
Show Gene links
Show Anatomy links
In vitro and in silico validation of CA3 and FHL1 downregulation in oral cancer.
Pereira CM
,
de Carvalho AC
,
da Silva FR
,
Melendez ME
,
Lessa RC
,
Andrade VCC
,
Kowalski LP
,
Vettore AL
,
Carvalho AL
.
???displayArticle.abstract???
BACKGROUND: Aberrant methylation is a frequent event in oral cancer.
METHODS: In order to better characterize these alterations, a search for genes downregulated by aberrant methylation in oral squamous cell carcinoma (OSCC) was conducted through the mining of ORESTES dataset. Findings were further validated in OSCC cell lines and patients'' samples and confirmed using TCGA data. Differentially expressed genes were identified in ORESTES libraries and validated in vitro using RT-PCR in HNSCC cell-lines and OSCC tumor samples. Further confirmation of these results was performed using mRNA expression and methylation data from The Cancer Genome Atlas (TCGA) data.
RESULTS: From the set of genes selected for validation, CA3 and FHL1 were downregulated in 60% (12/20) and 75% (15/20) of OSCC samples, respectively, and in HNSCC cell lines. The treatment of cell lines JHU-13 and FaDu with the demethylating agent 5''-aza-dC was efficient in restoring CA3 and FHL1 expression. TCGA expression and methylation data on OSCC confirms the downregulation of these genes in OSCC samples and also suggests that expression of CA3 and FHL1 is probably regulated by methylation. The downregulation of CA3 and FHL1 observed in silico was validated in HNSCC cell lines and OSCC samples, showing the feasibility of integrating different datasets to select differentially expressed genes in silico.
CONCLUSIONS: These results showed that the downregulation of CA3 and FHL1 data observed in the ORESTES libraries was validated in HNSCC cell lines and OSCC samples and in a large cohort of samples from the TCGA database. Moreover, it suggests that expression of CA3 and FHL1 could probably be regulated by methylation having an important role the oral carcinogenesis.
???displayArticle.pubmedLink???
29454310
???displayArticle.pmcLink???PMC5816396 ???displayArticle.link???BMC Cancer ???displayArticle.grants???[+]
05/02580-8 Fundação de Amparo à Pesquisa do Estado de São Paulo, 476586/2006-2 Conselho Nacional de Desenvolvimento Científico e Tecnológico
Fig. 1. RT-PCR analysis of CA3, FHL1, ANXA6, WDR26, HMGN4, C9orf64, FSTL1, CCN1, SAR1B and NFE2L1 expression in five HNSCC cell lines (represented above). Note, the expression of CA3 is not detectable in JHU-13 (O13) cell line and FHL1 is downregulated in FaDu cell line. Legend: (Ladder) 100 bp DNA Ladder (Invitrogen). + positive control (SW 480 tumor cell line) and NTC (no template control). ACTB mRNA was used to evaluate quantity in each RT-PCR reaction
Fig. 2. Gene expression profile of FHL1 and CA3 in 20 OSCC samples and 10 histologically normal oral mucosa samples. The Y-axis shows the log2 fold-change downregulation of the relative expression (2-ΔΔCt). The dotted line indicates the cut-off adopted (2-fold downregulation)
Fig. 3. In silico TCGA validation of mRNA expression and methylation data. Heatmap analysis from TCGA data for methylation status (β-values) and mRNA expression of CA3 and FHL1 genes in normal and OSCC samples. The black vertical line divides normal from tumor samples
Fig. 4. In silico TCGA evaluation of methylation status and mRNA expression of CA3 and FHL1. a and b boxplots show mean methylation β-values in normal and tumor tissues, for CA3 and FHL1 genes, respectively. c and d boxplots show mRNA expression distributions, in normal and tumor tissues, for CA3 and FHL1 genes, respectively. Statistical p values denote Student’s ttest between normal and OSCC samples. e and f show Pearson’s correlation of mean methylation β-values and mRNA expression, for CA3 and FHL1 genes, respectively
Fig. 5. RT-PCR assay for CA3 and FHL1 expression analysis after 5'-aza-dC treatment with 1 μM for 7 days. a Expression levels of CA3 in JHU-13 cell line. Note the gradative increase of CA3 expression from 3 to 7 days; b Expression levels of FHL1 in FaDu cell line. Note that FHL1 expression was restored at the third day of treatment. ACTB expression was used to evaluate the load quantity in each well. + positive control (HCT tumor cell line) and – negative control (without DNA)
Arantes,
Validation of methylation markers for diagnosis of oral cavity cancer.
2015, Pubmed
Arantes,
Validation of methylation markers for diagnosis of oral cavity cancer.
2015,
Pubmed
Arantes,
Methylation as a biomarker for head and neck cancer.
2014,
Pubmed
Barasch,
Oral cancer and oral effects of anticancer therapy.
1998,
Pubmed
Baylin,
Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?
2006,
Pubmed
Baylin,
DNA hypermethylation in tumorigenesis: epigenetics joins genetics.
2000,
Pubmed
Bhatia,
Promoter region hypermethylation and mRNA expression of MGMT and p16 genes in tissue and blood samples of human premalignant oral lesions and oral squamous cell carcinoma.
2014,
Pubmed
Brentani,
The generation and utilization of a cancer-oriented representation of the human transcriptome by using expressed sequence tags.
2003,
Pubmed
Brown,
Characterization of two isoforms of the skeletal muscle LIM protein 1, SLIM1. Localization of SLIM1 at focal adhesions and the isoform slimmer in the nucleus of myoblasts and cytoplasm of myotubes suggests distinct roles in the cytoskeleton and in nuclear-cytoplasmic communication.
1999,
Pubmed
Cabiscol,
The phosphatase activity of carbonic anhydrase III is reversibly regulated by glutathiolation.
1996,
Pubmed
Camargo,
The contribution of 700,000 ORF sequence tags to the definition of the human transcriptome.
2001,
Pubmed
Cao,
Methylation of p16 CpG island associated with malignant progression of oral epithelial dysplasia: a prospective cohort study.
2009,
Pubmed
Chakraborty,
Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma.
2008,
Pubmed
Chung,
Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression.
2004,
Pubmed
Das,
Understanding the biology of oral cancer.
2002,
Pubmed
Dessau,
[''R"--project for statistical computing].
2008,
Pubmed
Dias Neto,
Shotgun sequencing of the human transcriptome with ORF expressed sequence tags.
2000,
Pubmed
Fraser,
The mouse carbonic anhydrase I gene contains two tissue-specific promoters.
1989,
Pubmed
Ha,
Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma.
2006,
Pubmed
Jones,
Cancer epigenetics comes of age.
1999,
Pubmed
Jones,
The fundamental role of epigenetic events in cancer.
2002,
Pubmed
Koike,
High prevalence of epigenetic inactivation of the human four and a half LIM domains 1 gene in human oral cancer.
2013,
Pubmed
Kuo,
The differential expression of cytosolic carbonic anhydrase in human hepatocellular carcinoma.
2003,
Pubmed
Lallemant,
Gene expression profiling in head and neck squamous cell carcinoma: Clinical perspectives.
2010,
Pubmed
Lee,
Inactivation patterns of p16/INK4A in oral squamous cell carcinomas.
2004,
Pubmed
Leerkes,
In silico comparison of the transcriptome derived from purified normal breast cells and breast tumor cell lines reveals candidate upregulated genes in breast tumor cells.
2002,
Pubmed
Lessa,
Identification of upregulated genes in oral squamous cell carcinomas.
2013,
Pubmed
Livak,
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.
2001,
Pubmed
Lockyer,
Biomphalaria glabrata transcriptome: identification of cell-signalling, transcriptional control and immune-related genes from open reading frame expressed sequence tags (ORESTES).
2007,
Pubmed
Maia,
Identification of unannotated exons of low abundance transcripts in Drosophila melanogaster and cloning of a new serine protease gene upregulated upon injury.
2007,
Pubmed
McGregor,
Molecular changes associated with oral dysplasia progression and acquisition of immortality: potential for its reversal by 5-azacytidine.
2002,
Pubmed
Mello,
No-match ORESTES explored as tumor markers.
2009,
Pubmed
Morgan,
The structure of the human LIM protein ACT gene and its expression in tumor cell lines.
2000,
Pubmed
Nakahara,
High frequency of homozygous deletion and methylation of p16(INK4A) gene in oral squamous cell carcinomas.
2001,
Pubmed
Nakayama,
The E-cadherin gene is silenced by CpG methylation in human oral squamous cell carcinomas.
2001,
Pubmed
Ogi,
Aberrant methylation of multiple genes and clinicopathological features in oral squamous cell carcinoma.
2002,
Pubmed
Pruitt,
NCBI Reference Sequence (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins.
2005,
Pubmed
Reis,
Large-scale transcriptome analyses reveal new genetic marker candidates of head, neck, and thyroid cancer.
2005,
Pubmed
Robertson,
DNA methylation, methyltransferases, and cancer.
2001,
Pubmed
Sailasree,
Differential roles of p16INK4A and p14ARF genes in prognosis of oral carcinoma.
2008,
Pubmed
Shen,
SRC uses Cas to suppress Fhl1 in order to promote nonanchored growth and migration of tumor cells.
2006,
Pubmed
Shintani,
Inactivation of the p14(ARF), p15(INK4B) and p16(INK4A) genes is a frequent event in human oral squamous cell carcinomas.
2001,
Pubmed
Strausberg,
An international database and integrated analysis tools for the study of cancer gene expression.
2002,
Pubmed
Viswanathan,
Promoter hypermethylation profile of tumor-associated genes p16, p15, hMLH1, MGMT and E-cadherin in oral squamous cell carcinoma.
2003,
Pubmed
Wiklund,
MicroRNA alterations and associated aberrant DNA methylation patterns across multiple sample types in oral squamous cell carcinoma.
2011,
Pubmed
